17.13

0.59% 0.10

Moonlake Immunotherapeutics (MLTX)

Overview News Price History Option Chain Financials Why MLTX Down? Discussions Forecast

Moonlake Immunotherapeutics stock is traded at $17.13, with a volume of 678.58K. It is up +0.59% in the last 24 hours and up +8.62% over the past month. MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.

Previous Close:

$17.03

Open:

$17.14

24h Volume:

678.58K

Relative Volume:

0.34

Market Cap:

$1.23B

Revenue:

Net Income/Loss:

$-230.32M

P/E Ratio:

-4.8583

EPS:

-3.5259

Net Cash Flow:

$-196.04M

1W Performance:

-5.62%

1M Performance:

+8.62%

6M Performance:

-67.45%

1Y Performance:

-54.71%

1-Day Range:

$17.06

$17.79

1-Week Range:

$16.97

$19.34

52-Week Range:

$5.95

$62.75

Moonlake Immunotherapeutics Stock (MLTX) Company Profile

Name

Moonlake Immunotherapeutics

Sector

Healthcare (1115)

Industry

Biotechnology (621)

Phone

41 41 510 8022

Address

DORFSTRASSE 29, ZUG

Employee

130

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

MLTX's Discussions on Twitter

Compare MLTX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MLTX Moonlake Immunotherapeutics	17.13	1.23B	0	-230.32M	-196.04M	-3.5259
VRTX Vertex Pharmaceuticals Inc	469.34	119.23B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	745.77	78.84B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	700.45	43.35B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	313.41	41.57B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	284.05	31.51B	5.36B	287.73M	924.18M	2.5229

Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-15-26	Downgrade	Goldman	Neutral → Sell
Jan-09-26	Upgrade	BTIG Research	Neutral → Buy
Nov-03-25	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-02-25	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-01-25	Downgrade	Goldman	Buy → Neutral
Sep-30-25	Downgrade	Citigroup	Buy → Neutral
Sep-30-25	Downgrade	Wolfe Research	Outperform → Underperform
Sep-29-25	Downgrade	BTIG Research	Buy → Neutral
Sep-29-25	Downgrade	Jefferies	Buy → Hold
Sep-29-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-29-25	Downgrade	Stifel	Buy → Hold
Jul-28-25	Initiated	Rothschild & Co Redburn	Neutral
May-19-25	Upgrade	Wolfe Research	Peer Perform → Outperform
Mar-18-25	Initiated	RBC Capital Mkts	Outperform
Jan-17-25	Upgrade	Goldman	Neutral → Buy
Nov-05-24	Resumed	Wedbush	Outperform
Aug-26-24	Downgrade	Wolfe Research	Outperform → Peer Perform
Jun-25-24	Initiated	Oppenheimer	Outperform
Apr-02-24	Initiated	Goldman	Neutral
Feb-15-24	Initiated	Wolfe Research	Outperform
Dec-08-23	Initiated	Citigroup	Buy
Nov-02-23	Initiated	Stifel	Buy
Sep-14-23	Downgrade	Bryan Garnier	Buy → Neutral
Aug-31-23	Initiated	Needham	Buy
Jun-15-23	Initiated	Barclays	Equal Weight
May-01-23	Initiated	Guggenheim	Buy
Mar-22-23	Initiated	Wedbush	Outperform
Mar-09-23	Initiated	BTIG Research	Buy
Feb-14-23	Initiated	Cantor Fitzgerald	Overweight
Feb-02-23	Initiated	Bryan Garnier	Buy
Nov-11-22	Initiated	Jefferies	Buy
Aug-25-22	Initiated	SVB Leerink	Outperform
Jul-21-22	Initiated	H.C. Wainwright	Buy
Jul-07-22	Initiated	Cowen	Outperform

View All

Moonlake Immunotherapeutics Stock (MLTX) Latest News

Mar 15, 2026

Boxer Capital Management LLC Acquires New Holdings in MoonLake Immunotherapeutics $MLTX - MarketBeat

Mar 15, 2026

Mar 14, 2026

Avoro Capital Advisors LLC Cuts Stock Position in MoonLake Immunotherapeutics $MLTX - MarketBeat

Mar 14, 2026

Mar 13, 2026

TD Cowen Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating - 富途牛牛

Mar 13, 2026

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat

Mar 13, 2026

MLTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Mar 13, 2026

Mar 11, 2026

Clear Street Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $70 - 富途牛牛

Mar 11, 2026

Clear Street raises Moonlake stock price target on IL-17 data - Investing.com Nigeria

Mar 11, 2026

MoonLake price target raised to $70 from $45 at Clear Street - TipRanks

Mar 11, 2026

Clear Street raises Moonlake stock price target on IL-17 data By Investing.com - Investing.com Australia

Mar 11, 2026

Mar 10, 2026

How Investors Are Reacting To MoonLake Immunotherapeutics (MLTX) Widening Annual Net Loss Amid Share Price Gains - simplywall.st

Mar 10, 2026

Mar 09, 2026

Trading the Move, Not the Narrative: (MLTX) Edition - Stock Traders Daily

Mar 09, 2026

Mar 08, 2026

MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout - MSN

Mar 08, 2026

Mar 07, 2026

Is MoonLake Immunotherapeutics stock a smart buy before Fed meeting2026 EndofMonth & Verified Short-Term Trading Plans - Naître et grandir

Mar 07, 2026

TD Asset Management Inc Lowers Holdings in MoonLake Immunotherapeutics $MLTX - MarketBeat

Mar 07, 2026

MoonLake stock soars as biotech fund reloads, takeover chatter ignites - MSN

Mar 07, 2026

Mar 06, 2026

Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Positive Phase 2 Sonelokimab Results - simplywall.st

Mar 06, 2026

Mar 05, 2026

MoonLake Therapeutics Stock Sparks Retail Frenzy Ahead Of New York Summit — Traders See 'Nonstop Catalysts' Through 2026 - Stocktwits

Mar 05, 2026

HC Wainwright Issues Negative Outlook for MLTX Earnings - MarketBeat

Mar 05, 2026

Mar 04, 2026

What is HC Wainwright's Estimate for MLTX FY2027 Earnings? - MarketBeat

Mar 04, 2026

Mar 03, 2026

Wedbush Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $34 - 富途牛牛

Mar 03, 2026